AVTX logo

AVTX
Avalo Therapeutics Inc

13,687
Mkt Cap
$404.72M
Volume
1.1M
52W High
$20.72
52W Low
$3.39
PE Ratio
-2.67
AVTX Fundamentals
Price
$16.27
Prev Close
$17.76
Open
$18.13
50D MA
$15.54
Beta
1.71
Avg. Volume
809,789.18
EPS (Annual)
-$5.84
P/B
3.63
Rev/Employee
$1,787.88
$147.49
Loading...
Loading...
News
all
press releases
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Small drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments.
Zacks·14h ago
News Placeholder
More News
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) Earns Market Outperform Rating from Analysts at Citizens Jmp
Citizens Jmp initiated coverage on shares of Avalo Therapeutics in a report on Monday. They issued a "market outperform" rating and a $52.00 price objective on the stock...
MarketBeat·17h ago
News Placeholder
Christopher Ryan Sullivan Sells 7,979 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 7,979 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an...
MarketBeat·3d ago
News Placeholder
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by Analysts
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat reports. One...
MarketBeat·3d ago
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Mittie Doyle sold 679 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price...
MarketBeat·3d ago
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 7,979 shares of the business's stock in a transaction on Wednesday, April 1st. The stock was sold at an...
MarketBeat·3d ago
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 7,980 shares of the firm's stock in a transaction dated Thursday, April 2nd. The stock was sold at an...
MarketBeat·3d ago
News Placeholder
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Avalo Therapeutics (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·4d ago
News Placeholder
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Zacks·5d ago
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen upgraded Avalo Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·9d ago
<
1
2
...
>

Latest AVTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.